Serotonin receptor signaling and regulation via β-arrestins

Critical Reviews in Biochemistry and Molecular Biology

Volumn 45, Issue 6, 2010, Pages 555-566

  Bohn, Laura M ^a   Schmid, Cullen L ^a,b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

5 hydroxytryptamine (5 HT); functional selectivity; G protein coupled receptor; homologous desensitization; receptor trafficking

Indexed keywords

BETA ARRESTIN; CLOZAPINE; G PROTEIN COUPLED RECEPTOR; OLANZAPINE; RISPERIDONE; SEROTONIN 2A AGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR;

DRUG TARGETING; HUMAN; IN VIVO STUDY; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ARRESTINS; CENTRAL NERVOUS SYSTEM; HALLUCINOGENS; HUMANS; NEURONS; PERIPHERAL NERVOUS SYSTEM; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN RECEPTOR AGONISTS; SIGNAL TRANSDUCTION;

EID: 78549240579     PISSN: 10409238     EISSN: 15497798     Source Type: Journal    
DOI: 10.3109/10409238.2010.516741     Document Type: Review

References (104)

1. Abbas AI, Yadav PN, Yao WD, Arbuckle MI, Grant SG, Caron MG and Roth BL. 2009. PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J Neurosci 29:7124-7136.
2. Aghajanian GK and Marek GJ. 1999. Serotonin and hallucinogens. Neuropsychopharmacology 21:16S-23S.
3. Ahn S, Nelson CD, Garrison TR, Miller WE and Lefkowitz RJ. 2003. Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference. Proc Natl Acad Sci USA 100:1740-1744.
4. Attramadal H, Arriza JL, Aoki C, Dawson TM, Codina J, Kwatra MM, Snyder SH, Caron MG and Lefkowitz RJ. 1992. Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family. J Biol Chem 267:17882-17890.
5. Barak LS, Ferguson SS, Zhang J and Caron MG. 1997. A beta-arrestin/ green fuorescent protein biosensor for detecting G protein-coupled receptor activation. J Biol Chem 272:27497-27500.
6. Barthet G, Gaven F, Framery B, Shinjo K, Nakamura T, Claeysen S, Bockaert J and Dumuis A. 2005. Uncoupling and endocyto-sis of 5-b hydroxytryptamine 4 receptors. Distinct molecular events with diferent GRK2 requirements. J Biol Chem 280:27924-27934.
7. Barthet G, Framery B, Gaven F, Pellissier L, Reiter E, Claeysen S, Bockaert J and Dumuis A. 2007. 5-hydroxytryptamine 4 receptor activation of the extracellular signal-regulated kinase pathway depends on Src activation but not on G protein or beta-arrestin signaling. Mol Biol Cell 18:1979-1991.
8. Barthet G, Carrat G, Cassier E, Barker B, Gaven F, Pillot M, Framery B, Pellissier LP, Augier J, Kang DS, Claeysen S, Reiter E, Baneres JL, Benovic JL, Marin P, Bockaert J and Dumuis A. 2009. Beta-arrestin1 phosphorylation by GRK5 regulates G protein- independent 5-HT4 receptor signalling. EMBO J 28:2706-2718.
9. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR and Caron MG. 2005. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261-273.
10. Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V, Wetsel WC, Lefkowitz RJ, Gainetdinov RR and Caron MG. 2008. A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132:125-136.
11. Berg KA, Clarke WP, Cunningham KA and Spampinato U. 2008. Fine-tuning serotonin2c receptor function in the brain: molecular and functional implications. Neuropharmacology 55:969-976.
12. Berry SA, Shah MC, Khan N and Roth BL. 1996. Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro. Mol Pharmacol 50:306-313.
13. Bhatnagar A, Willins DL, Gray JA, Woods J, Benovic JL and Roth BL. 2001. The dynamin-dependent, arrestin-independent internali-zation of 5-hydroxytryptamine 2A (5-HT2A) serotonin receptors reveals diferential sorting of arrestins and 5-HT2A receptors during endocytosis. J Biol Chem 276:8269-8277.
14. Bhattacharya A, Sankar S and Panicker MM. 2010. Diferences in the C-terminus contribute to variations in Traficking between rat and human 5-HT(2A) receptor isoforms: identifca-tion of a primate-specifc tripeptide ASK motif that confers GRK-2 and beta arrestin-2 interactions. J Neurochem 112: 723-732.
15. Blondel O, Gastineau M, Dahmoune Y, Langlois M and Fischmeister R. 1998. Cloning, expression, and pharmacology of four human 5-hydroxytryptamine 4 receptor isoforms produced by alternative splicing in the carboxyl terminus. J Neurochem 70:2252-2261.
16. Bockaert J, Claeysen S, Compan V and Dumuis A. 2004. 5-HT4 receptors. Curr Drug Targets CNS Neurol Disord 3:39-51.
17. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG and Lin FT. 1999. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286:2495-2498.
18. Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ and Caron MG. 2000. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408:720-723.
19. Bohn LM, Lefkowitz RJ and Caron MG. 2002. Diferential mechanisms of morphine antinociceptive tolerance revealed in (beta)arres-tin-2 knock-out mice. J Neurosci 22:10494-10500.
20. Bohn LM, Dykstra LA, Lefkowitz RJ, Caron MG and Barak LS. 2004. Relative opioid efcacy is determined by the complements of the G protein-coupled receptor desensitization machinery. Mol Pharmacol 66:106-112.
21. Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E and Emeson RB. 1997. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 387:303-308.
22. Claeysen S, Faye P, Sebben M, Taviaux S, Bockaert J and Dumuis A. 1998. 5-HT4 receptors: cloning and expression of new splice variants. Ann NY Acad Sci 861, 49-56.
23. Claeysen S, Sebben M, Becamel C, Bockaert J and Dumuis A. 1999. Novel brain-specifc 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. Mol Pharmacol 55:910-920.
24. Claeysen S, Sebben M, Becamel C, Parmentier ML, Dumuis A and Bockaert J. 2001. Constitutively active mutants of 5-HT4 receptors are they in unique active states? EMBO Rep 2:61-67.
25. Conn PJ and Sanders-Bush E. 1984. Selective 5HT-2 antagonists inhibit serotonin stimulated phosphatidylinositol metabolism in cerebral cortex. Neuropharmacology 23:993-996.
26. Conn PJ and Sanders-Bush E. 1986. Regulation of serotonin-stimulated phosphoinositide hydrolysis: relation to the serotonin 5-HT-2 binding site. J Neurosci 6:3669-3675.
27. Conner DA, Mathier MA, Mortensen RM, Christe M, Vatner SF, Seidman CE and Seidman JG. 1997. beta-Arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to beta-adrenergic stimulation. Circ Res 81:1021-1026.
28. Cornea-Hebert V, Riad M, Wu C, Singh SK and Descarries L. 1999. Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J Comp Neurol 409:187-209.
29. Cornea-Hebert V, Watkins KC, Roth BL, Kroeze WK, Gaudreau P, Leclerc N and Descarries L. 2002. Similar ultrastructural distribution of the 5-HT(2A) serotonin receptor and microtubule-associated protein MAP1A in cortical dendrites of adult rat. Neuroscience 113:23-35.
30. Daaka Y, Luttrell LM, Ahn S, Della Rocca GJ, Ferguson SS, Caron MG and Lefkowitz RJ. 1998. Essential role for G protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase. J Biol Chem 273:685-688.
31. DeWire SM, Ahn S, Lefkowitz RJ and Shenoy SK. 2007. Beta-arrestins and cell signaling. Annu Rev Physiol 69:483-510.
32. Drake MT, Violin JD, Whalen EJ, Wisler JW, Shenoy SK and Lefkowitz RJ. 2008. beta-arrestin-biased agonism at the beta2-adrenergic receptor. J Biol Chem 283:5669-5676.
33. Dumuis A, Bouhelal R, Sebben M, Cory R and Bockaert J. 1988. A non-classical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system. Mol Pharmacol 34:880-887. (Pubitemid 19014410)
34. Ferguson SS. 2001. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53:1-24.
35. Ferguson SS, Downey WE, 3rd, Colapietro AM, Barak LS, Menard L and Caron MG. 1996. Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 271:363-366.
36. Gelber EI, Kroeze WK, Willins DL, Gray JA, Sinar CA, Hyde EG, Gurevich V, Benovic J and Roth BL. 1999. Structure and function of the third intracellular loop of the 5-hydroxytryptamine2A receptor: the third intracellular loop is alpha-helical and binds purifed arrestins. J Neurochem 72:2206-2214.
37. Giorgetti M and Tecott LH. 2004. Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. Eur J Pharmacol 488:1-9.
38. Gonzalez-Maeso J, Weisstaub N V, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC and Gingrich JA. 2007. Hallucinogens recruit specifc cortical 5-HT(2A) receptor- mediated signaling pathways to afect behavior. Neuron 53:439-452.
39. Goodman OB, Jr, Krupnick JG, Santini F, Gurevich VV, Penn RB, Gagnon AW, Keen JH and Benovic JL. 1996. Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature 383:447-450.
40. Gray JA and Roth BL. 2001. Paradoxical Traficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull 56:441-451.
41. Gray JA, Shefer DJ, Bhatnagar A, Woods JA, Hufeisen SJ, Benovic JL and Roth BL. 2001. Cell-type specifc efects of endocytosis inhibitors on 5-hydroxytryptamine(2A) receptor desensitiza-tion and resensitization reveal an arrestin-, GRK2-, and GRK5-independent mode of regulation in human embryonic kidney 293 cells. Mol Pharmacol 60:1020-1030.
42. Gray JA, Bhatnagar A, Gurevich VV and Roth BL. 2003. The interaction of a constitutively active arrestin with the arrestin-insensitive 5-HT(2A) receptor induces agonist-independent internalization. Mol Pharmacol 63:961-972.
43. Gray-Keller MP, Detwiler PB, Benovic JL and Gurevich V V. 1997. Arrestin with a single amino acid substitution quenches light-activated rhodopsin in a phosphorylation-independent fashion. Biochemistry 36:7058-7063.
44. Groer CE, Tidgewell K, Moyer RA, Harding WW, Rothman RB, Prisinzano The and Bohn LM. 2007. An opioid agonist that does not induce micro-opioid receptor-arrestin interactions or receptor internalization. Mol Pharmacol 71:549-557.
45. Gurevich VV and Gurevich E V. 2006. The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacol Ter 110:465-502.
46. Gurevich VV, Dion SB, Onorato JJ, Ptasienski J, Kim CM, Sterne-Marr R, Hosey MM and Benovic JL. 1995. Arrestin interactions with G protein-coupled receptors. Direct binding studies of wild type and mutant arrestins with rhodopsin, beta 2-adrenergic, and m2 muscarinic cholinergic receptors. J Biol Chem 270:720-731.
47. Gurevich E V, Benovic JL and Gurevich VV. 2002. Arrestin2 and arres-tin3 are diferentially expressed in the rat brain during postnatal development. Neuroscience 109:421-436.
48. Hamdan FF, Audet M, Garneau P, Pelletier J and Bouvier M. 2005. High-throughput screening of G protein-coupled receptor antagonists using a bioluminescence resonance energy transfer 1-based beta-arrestin2 recruitment assay. J Biomol Screen 10:463-475.
49. Hanley NR and Hensler JG. 2002. Mechanisms of ligand-induced desensitization of the 5-hydroxytryptamine(2A) receptor. J Pharmacol Exp Ter 300:468-477.
50. Ivins KJ and Molinof PB. 1991. Desensitization and down-regulation of 5-HT2 receptors in P11 cells. J Pharmacol Exp Ter 259:423-429.
51. Iwamoto K, Bundo M and Kato T. 2009. Serotonin receptor 2C and mental disorders: genetic, expression and RNA editing studies. RNA Biol 6:248-253.
52. Joubert L, Hanson B, Barthet G, Sebben M, Claeysen S, Hong W, Marin P, Dumuis A and Bockaert J. 2004. New sorting nexin (SNX27) and NHERF specifcally interact with the 5-HT4a receptor splice variant: roles in receptor targeting. J Cell Sci 117:5367-5379.
53. Kenakin T. 1995. Agonist-receptor efcacy. II. Agonist Traficking of receptor signals. Trends Pharmacol Sci 16:232-238.
54. Kim HS. 2009. 5-Hydroxytryptamine4 receptor agonists and colonic motility. J Smooth Muscle Res 45:25-29.
55. Kim YM and Benovic JL. 2002. Diferential roles of arrestin-2 interaction with clathrin and adaptor protein 2 in G protein-coupled receptor Traficking. J Biol Chem 277:30760-30708.
56. Kobilka BK and Deupi X. 2007. Conformational complexity of G-protein-coupled receptors. Trends Pharmacol Sci 28:397-406.
57. Kohout TA, Lin FS, Perry SJ, Conner DA and Lefkowitz RJ. 2001. beta-Arrestin 1 and 2 diferentially regulate heptahelical receptor signaling and Traficking. Proc Natl Acad Sci USA 98:1601-1606.
58. Kovacs JJ, Hara MR, Davenport CL, Kim J and Lefkowitz RJ. 2009. Arrestin development: emerging roles for beta-arrestins in developmental signaling pathways. Dev Cell 17:443-458.
59. Kovoor A, Celver J, Abdryashitov RI, Chavkin C and Gurevich V V. 1999. Targeted construction of phosphorylation-independent beta-arrestin mutants with constitutive activity in cells. J Biol Chem 274:6831-6834.
60. Krupnick JG, Santini F, Gagnon AW, Keen JH and Benovic JL. 1997. Modulation of the arrestin-clathrin interaction in cells. Characterization of beta-arrestin dominant-negative mutants. J Biol Chem 272:32507-32512.
61. Labasque M, Reiter E, Becamel C, Bockaert J and Marin P. 2008. Physical interaction of calmodulin with the 5-hydroxytryp-tamine2C receptor C-terminus is essential for G protein-independent, arrestin-dependent receptor signaling. Mol Biol Cell 19:4640-4650.
62. Laporte SA, Oakley RH, Zhang J, Holt JA, Ferguson SS, Caron MG and Barak LS. 1999. The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci USA 96:3712-3717.
63. Lefkowitz RJ and Shenoy SK. 2005. Transduction of receptor signals by beta-arrestins. Science 308:512-517.
64. Leysen JE. 2004. 5-HT2 receptors. Curr Drug Targets CNS Neurol Disord 3:11-26.
65. Liu Y, Emeson RB and Samuel CE. 1999. Serotonin-2C receptor pre-mRNA editing in rat brain and in vitro by splice site variants of the interferon-inducible double-stranded RNA-specifc adenosine deaminase ADAR1. J Biol Chem 274:18351-18358.
66. Luttrell LM and Lefkowitz RJ. 2002. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 115:455-465.
67. Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, Lin F, Kawakatsu H, Owada K, Luttrell DK, Caron MG and Lefkowitz RJ. 1999. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283:655-661.
68. Maes M and Meltzer HY. 1995. The serotonin hypothesis of major depression. In: Bloom FE and Kupfer DJ (eds) Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press.
69. Marion S, Oakley RH, Kim KM, Caron MG and Barak LS. 2006. A beta-arrestin binding determinant common to the second intracellu-lar loops of rhodopsin family G protein-coupled receptors. J Biol Chem 281:2932-2938.
70. Marion S, Weiner DM and Caron MG. 2004. RNA editing induces variation in desensitization and Traficking of 5-hydroxytryptamine 2c receptor isoforms. J Biol Chem 279:2945.
71. McDonald PH and Bohn LM. 2010. Seeking ligand bias: assessing GPCR coupling to beta-arrestins for drug discovery. Drug Discovery Today (in press).
72. McDonald PH, Chow CW, Miller WE, Laporte SA, Field ME, Lin FT, Davis RJ and Lefkowitz RJ. 2000. Beta-arrestin 2: a receptor-regulated MAPK scafold for the activation of JNK3. Science 290:1574-1577.
73. Meltzer HY. 2002. Mechanism of action of atypical antipsychotic drugs. In: Davis KL, Charney D, Coyle JT and Nemerof C. (eds) Neuropsychopharmacology: The Fifth Generation of Progress. New York: Raven Press.
74. Menard L, Ferguson SS, Zhang J, Lin FT, Lefkowitz RJ, Caron MG and Barak LS. 1997. Synergistic regulation of beta2-adrenergic receptor sequestration: intracellular complement of beta-adren-ergic receptor kinase and beta-arrestin determine kinetics of internalization. Mol Pharmacol 51:800-808.
75. Millan MJ. 2005. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Terapie 60:441-460.
76. Mnie-Filali O, Amraei MG, Benmbarek S, Archer-Lahlou E, Penas-Cazorla R, Vilaro MT, Boye SM and Pineyro G. 2010. Serotonin 4 receptor (5-HT4R) internalization is isoform-specifc: efects of 5-HT and RS67333 on isoforms A and B. Cell Signal 22:501-509.
77. Nichols DE. 2004. Hallucinogens. Pharmacol Ter 101:131-181.
78. Niswender CM, Sanders-Bush E and Emeson RB. 1998. Identifcation and characterization of RNA editing events within the 5-HT2C receptor. Ann NY Acad Sci 861:38-48.
79. Oakley RH, Laporte SA, Holt JA, Caron MG and Barak LS. 2000. Diferential afnities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 275:17201-17210.
80. Orsini MJ and Benovic JL. 1998. Characterization of dominant negative arrestins that inhibit beta2-adrenergic receptor internalization by distinct mechanisms. J Biol Chem 273:34616-34622.
81. 4 receptors. Mol Pharmacol 41, 346-351.
82. Pierce KL and Lefkowitz RJ. 2001. Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors. Nat Rev Neurosci 2:727-733.
83. Pieri L, Keller HH, Burkard W and Da Prada M. 1978. Efects of lisu-ride and LSD on cerebral monoamine systems and hallucinosis. Nature 272:278-280.
84. Ponimaskin E, Dumuis A, Gaven F, Barthet G, Heine M, Glebov K, Richter DW and Oppermann M. 2005. Palmitoylation of the 5-hy-droxytryptamine4a receptor regulates receptor phosphorylation, desensitization, and beta-arrestin-mediated endocytosis. Mol Pharmacol 67:1434-1443.
85. Roth BL and Meltzer HY. 1995. The role of serotonin in schizophrenia. In: Bloom FE and Kupfer DJ. (eds) Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press.
86. Roth BL, Nakaki T, Chuang DM and Costa E. 1984. Aortic recognition sites for serotonin (5HT) are coupled to phospholipase C and modulate phosphatidylinositol turnover. Neuropharmacology 23:1223-1225.
87. Roth BL, Palvimaki EP, Berry S, Khan N, Sachs N, Uluer A and Choudhary MS. 1995. 5-Hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation. J Pharmacol Exp Ter 275:1638-1646.
88. Roth BL, Berry SA, Kroeze WK, Willins DL and Kristiansen K. 1998. Serotonin 5-HT2A receptors: molecular biology and mechanisms of regulation. Crit Rev Neurobiol 12:319-338.
89. Schmid CL and Bohn LM. 2009. Physiological and pharmacological implications of beta-arrestin regulation. Pharmacol Ter 121:285-293.
90. Schmid CL and Bohn LM. 2010. Serotonin, but not N-Methyltryptamines, activates the Serotonin 2A Receptor via a barrestin2/Src/AKT signaling complex in vivo. J Neurosci 30:13513-13524.
91. Schmid CL, Raehal KM and Bohn LM. 2008. Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci USA 105:1079-1084.
92. Shenoy SK and Lefkowitz RJ. 2003. Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor Trafick-ing and signalling. Biochem J 375:503-515.
93. Stalheim L, Ding Y, Gullapalli A, Paing MM, Wolfe BL, Morris DR and Trejo J. 2005. Multiple independent functions of arrestins in the regulation of protease-activated receptor-2 signaling and Trafick-ing. Mol Pharmacol 67:78-87.
94. Urban JD, Clarke WP, Von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M and Mailman RB. 2007. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ter 320:1-13.
95. von Degenfeld G, Wehrman TS, Hammer MM and Blau HM. 2007. A universal technology for monitoring G-protein-coupled receptor activation in vitro and noninvasively in live animals. Faseb J 21:3819-3826.
96. Wang Q, Zhao J, Brady AE, Feng J, Allen PB, Lefkowitz RJ, Greengard P and Limbird LE. 2004. Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. Science 304:1940-1944.
97. Werry TD, Gregory KJ, Sexton PM and Christopoulos A. 2005. Characterization of serotonin 5-HT2C receptor signaling to extracellular signal-regulated kinases 1 and 2. J Neurochem 93:1603-1615.
98. Werry TD, Christopoulos A and Sexton PM. 2006. Mechanisms of ERK1/2 regulation by seven-transmembrane-domain receptors. Curr Pharm Des 12:1683-1702.
99. Willins DL, Deutch AY and Roth BL. 1997. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 27:79-82.
100. Xia Z, Hufeisen SJ, Gray JA and Roth BL. 2003. The PDZ-binding domain is essential for the dendritic targeting of 5-HT2A serotonin receptors in cortical pyramidal neurons in vitro. Neuroscience 122:907-920.
101. Yuen EY, Jiang Q, Chen P, Feng J and Yan Z. 2008. Activation of 5-HT2A/C receptors counteracts 5-HT1A regulation of n-methyl-D-aspartate receptor channels in pyramidal neurons of prefrontal cortex. J Biol Chem 283:17194-17204.
102. Yusuf S, Al-Saady N and Camm AJ. 2003. 5-hydroxytryptamine and atrial fbrillation: how signifcant is this piece in the puzzle? J Cardiovasc Electrophysiol 14:209-214.
103. Zhang J, Barak LS, Winkler KE, Caron MG and Ferguson SS. 1997. A central role for beta-arrestins and clathrin-coated vesicle-mediated endocytosis in beta2-adrenergic receptor resensitization. Diferential regulation of receptor resensitization in two distinct cell types. J Biol Chem 272:27005-27014.
104. Zhang J, Ferguson SS, Barak LS, Bodduluri SR, Laporte SA, Law PY and Caron MG. 1998. Role for G protein-coupled receptor kinase in agonist-specifc regulation of mu-opioid receptor responsiveness. Proc Natl Acad Sci USA 95:7157-7162.